Long Non-Coding RNA (LncRNA)-ATB Promotes Inflammation, Cell Apoptosis and Senescence in Transforming Growth Factor-β1 (TGF-β1) Induced Human Kidney 2 (HK-2) Cells Via TGFβ/SMAD2/3 Signaling Pathway
Overview
Pathology
Affiliations
BACKGROUND Renal fibrosis occurs in the end-stage of all chronic kidney disease. Transforming growth factor-ß1 (TGF-ß1) is a central contributor in fibrosis. Identifying effective biomarkers that targets TGF-ß1 is necessary for the development of therapeutic agents for kidney disease. In this study, we investigated the effects and mechanism of long non-coding RNA (LncRNA)-ATB in TGF-ß1 induced human kidney 2 (HK-2) cells. MATERIAL AND METHODS We investigated the effects of either overexpression or knockdown of LncRNA-ATB on inflammation, cell apoptosis, and senescence in TGF-ß1 induced HK-2 cells. TGF-ß1 induced HK-2 cells served as the cell model. The gene level was evaluated by quantitative real-time polymerase chain reaction (qRT-PCR) and protein expressions by western blot. Cell Counting Kit-8 (CCK-8) assay was performed for assessment of cell viability. Flow cytometry was applied for detection of cell apoptosis. Tumor necrosis factor (TNF)-alpha, interleukin (IL)-1ß, and IL-6 were measured by corresponding kits. RESULTS LncRNA-ATB was highly expressed in TGF-ß1 induced HK-2 cells. Inflammation, cell apoptosis, and senescence were enhanced by TGF-ß1 and these effects were all reduced by knockdown of LncRNA-ATB. Whereas overexpression of LncRNA-ATB had the opposite effects with knockdown of LncRNA-ATB. The TGFß/SMAD2/3 signaling pathway was activated by TGF-ß1 and this effect was further enhanced by LncRNA-ATB overexpression. Silencing LncRNA-ATB inhibited the TGFß/SMAD2/3 signaling pathway in TGF-ß1 induced cells. The effects of LncRNA-ATB overexpression aforementioned in TGF-ß1 induced cells were abolished by blockage of the TGFß/S0MAD2/3 signaling pathway. CONCLUSIONS LncRNA-ATB overexpression have promoting effects on inflammation, cell apoptosis and senescence in TGF-ß1 induced HK-2 cells via activating the TGFß/SMAD2/3 signaling pathway. LncRNA-ATB act as a key downstream mediator via activating the TGFß/SMAD2/3 signaling pathway and silencing LncRNA-ATB might be a new strategy for chronic kidney disease treatment.
Update of cellular senescence in kidney fibrosis: from mechanism to potential interventions.
Yang L, Ma L, Fu P, Nie J Front Med. 2025; .
PMID: 40011387 DOI: 10.1007/s11684-024-1117-z.
Role of LncRNA in Pathogenesis, Diagnosis and Treatment of Chronic Kidney Disease.
He X, Li H Cell Biochem Biophys. 2025; .
PMID: 40000585 DOI: 10.1007/s12013-025-01698-2.
Kidney Aging and Chronic Kidney Disease.
Zhang Y, Yu C, Li X Int J Mol Sci. 2024; 25(12).
PMID: 38928291 PMC: 11204319. DOI: 10.3390/ijms25126585.
Roles of long noncoding RNAs in human inflammatory diseases.
Zhang Y, Liu H, Niu M, Wang Y, Xu R, Guo Y Cell Death Discov. 2024; 10(1):235.
PMID: 38750059 PMC: 11096177. DOI: 10.1038/s41420-024-02002-6.
TGF-β as A Master Regulator of Aging-Associated Tissue Fibrosis.
Ren L, Miao H, Wang Y, Liu F, Li P, Zhao Y Aging Dis. 2023; 14(5):1633-1650.
PMID: 37196129 PMC: 10529747. DOI: 10.14336/AD.2023.0222.